Australia's most trusted source of pharma news
Tuesday, 24 October 2017
News Headlines
Search News Archive
Perspective
Whither the GBMA in a biosim dominated market?
The departure of Belinda Wood from the helm of the GBMA presents an opportunity to consider what role this group can play in the future Australian medicines market.
The departure of Belinda Wood from the helm of the GBMA presents an opportunity to consider what role this group can play in the future Australian medicines market.
Approvals Action
New heart pain drug registered
Menarini has registered a new heart pain drug while Sanofi continues to add to Clexane options to address its impending patent expiry.
Menarini has registered a new heart pain drug while Sanofi continues to add to Clexane options to address its impending patent expiry.
Pipeline Monitor
Gilead scores first win from Kite buyout
Gilead has received its first FDA approval for newly acquired CAR-T Yescarta following its USD12 billion buyout of original sponsor Kite Pharma in August.
Gilead has received its first FDA approval for newly acquired CAR-T Yescarta following its USD12 billion buyout of original sponsor Kite Pharma in August.